Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $9.33 USD
Change Today -0.47 / -4.80%
Volume 21.9K
ADMA On Other Exchanges
As of 5:20 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

adma biologics inc (ADMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/3/14 - $14.00
52 Week Low
04/30/14 - $6.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ADMA BIOLOGICS INC (ADMA)

Related News

No related news articles were found.

adma biologics inc (ADMA) Related Businessweek News

No Related Businessweek News Found

adma biologics inc (ADMA) Details

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. Its lead product candidate is RI-002, which is in Phase III clinical trial intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

60 Employees
Last Reported Date: 03/9/15
Founded in 2004

adma biologics inc (ADMA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $484.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $343.9K
Chief Scientific & Medical Officer and Execut...
Total Annual Compensation: $320.5K
Compensation as of Fiscal Year 2013.

adma biologics inc (ADMA) Key Developments

ADMA Biologics, Inc. Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2014

ADMA Biologics, Inc. reported audited consolidated earnings results for the year ended December 31, 2014. For the year, the company reported total revenues of $5,915,545 against $3,067,577 a year ago. Loss from operations was $16,018,533 against $15,042,431 a year ago. Loss before income taxes was $17,364,887 against $15,527,246 a year ago. Net loss was $16,813,163 or $1.81 per basic and diluted share against $15,527,246 or $2.38 per basic and diluted share a year ago. The increased year-over-year net loss was primarily attributed to higher research and development expenses of $9.5 million during the year ended 2014, compared to $9.3 million during the year ended 2013, as a result of completing fully enrolled Phase III clinical study during the fourth quarter 2014, along with increased non-cash stock-based compensation charges. Additionally, overall net loss increased as a result of increased costs of plasma product expenses attributed to increased plasma revenues, donor collections and associated costs, increased plasma center operating costs attributed to advertising and promotion expenses, increased headcount and capital expenditures for two plasma facilities, and increased plasma centers' general and administrative costs.

ADMA Biologics, Inc. Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference

ADMA Biologics, Inc. announced positive results on the primary and secondary endpoint evaluations from its pivotal Phase III trial for RI-002 in Primary Immune Deficiency Disease (PIDD) in a poster presentation at the American Academy of Allergy, Asthma and Immunology Annual Meeting. In December 2014, the company announced that the trial met its primary endpoint with zero serious bacterial infections (SBI). In this multi-site study of 59 patients diagnosed with PIDD, investigators reported on the secondary endpoints that included: a total of 93 days, or 1.66 days per patient per year lost from work or school due to infection; one hospitalization due to an infection of only five days duration in the entire study and IgG trough levels above those required by the FDA for IVIG products. Additionally, there was a marked increase in all of the measured specific anti-pathogen antibodies in PK subjects (n=31), with the great increase, 5.3 fold, seen in the level of neutralizing antibody titers to RSV. The safety profile of RI-002 was comparable to that of other immunoglobulins. These encouraging secondary end point results follow the prior announcement that the trial achieved its primary endpoint with zero reported acute serious bacterial infections (SBI) in the course of the trial.

ADMA Biologics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 03:30 PM

ADMA Biologics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 03:30 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Adam S. Grossmann, Founder, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMA:US $9.33 USD -0.47

ADMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADMA.
View Industry Companies

Industry Analysis


Industry Average

Valuation ADMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.4x
Price/Book 14.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADMA BIOLOGICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at